# Dirk Winkler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dirk-winkler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,959 |
| Field | Chronic Lymphocytic Leukemia Research |
| h-index | 43 |
| i10-index | 123 |
| OpenAlex ID | https://openalex.org/A5005408617 |
| ORCID iD | 0000-0003-4298-010X |
| Works | 280 |

## Researcher papers

- [Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/addition-of-rituximab-to-fludarabine-and-cyclophosphamide-in-patients-with/)
- [<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia](https://scholariq.org/papers/i-tp53-i-mutation-and-survival-in-chronic-lymphocytic-leukemia/)
- [Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial](https://scholariq.org/papers/gene-mutations-and-treatment-outcome-in-chronic-lymphocytic-leukemia-results/)
- [Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-in-combination-with-rituximab-for-previously-untreated-patients/)
- [Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up](https://scholariq.org/papers/monoallelic-tp53-inactivation-is-associated-with-poor-prognosis-in-chronic/)
- [Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-combined-with-rituximab-in-patients-with-relapsed-and-or-refractory/)
- [Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial](https://scholariq.org/papers/allogeneic-stem-cell-transplantation-provides-durable-disease-control-in-poor/)
- [Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial](https://scholariq.org/papers/detailed-analysis-of-p53-pathway-defects-in-fludarabine-refractory-chronic/)
- [Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion](https://scholariq.org/papers/peptide-arrays-on-cellulose-support-spot-synthesis-a-time-and-cost-efficient/)
- [miR-34a as part of the resistance network in chronic lymphocytic leukemia](https://scholariq.org/papers/mir-34a-as-part-of-the-resistance-network-in-chronic-lymphocytic-leukemia/)
- [Functional improvement of patients with Parkinson syndromes using a rehabilitation training software](https://scholariq.org/papers/functional-improvement-of-patients-with-parkinson-syndromes-using-a/)

## Researcher topics

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)
- [Neurological disorders and treatments](https://scholariq.org/topics/neurological-disorders-and-treatments/)
- [Chemical Synthesis and Analysis](https://scholariq.org/topics/chemical-synthesis-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.